Disease modification in SLE: when is the window of opportunity? - Industry Session Supported by GSK

Session Description:

For this symposium, world-renowned experts will focus on key considerations and data that support the importance to treat the underlying disease in patients with active systemic lupus erythematosus (SLE). Experts will highlight key treatment challenges and how targeted treatment approaches can improve long-term patient outcomes. Efficacy and safety data, including real-world evidence will be reviewed to support early intervention with Benlysta ▼ (belimumab). This will help physicians to be aligned on short-term and long-term treatment goals to control active disease and/or flares, while at the same time, reducing the risk of organ damage accrual. This will suggest how a targeted therapy can support disease modification to minimise organ damage and improve patient outcomes in SLE. An industry symposium sponsored and organised by GSK. GSK products will be discussed at this meeting.

Benlysta GB PI is available here.

Benlysta Northern Ireland is available here.

Management of ILD with and without progressive pulmonary fibrosis in ARDs - Industry Session Supported by BOEHRINGER INGELHEIM ITALIA

The debate sessions at CORA 2023 are the heart of the Congress where scientists passionately defend their convictions on burning issues. Each of the two debaters has 15 minutes for their presentation followed by 5 minutes per speaker for a rebuttal and 15 minutes for a discussion and Q&A led by the chairperson.

Driving elevated real-world outcomes in SLE – an expert-led roundtable discussion - Industry Session Supported by AstraZenecaSession Description: In this session, Andrea Doria (Italy) will chair a dynamic roundtable discussion with the expert faculty to explore the challenges, opportunities and practical management strategies in SLE, including real-world experience with anifrolumab.Peter Korsten (Germany) will kick-off the session by outlining the importance of achieving comprehensive disease control in SLE through presentation of his own real-world clinical case and encouraging reflection and discussion on disease management with our faculty and audience.Fulvia Ceccarelli (Italy) will explore more of Dr Korsten’s clinical case highlighting the role of glucocorticoids in SLE treatment and consider strategies for optimising their use in clinical practice, including a practical focus on where, when and how to adjust glucocorticoid dose. Finally, Ian Bruce (UK) will present the long-term extension data for anifrolumab and consider its potential role in driving sustained improved outcomes for your patients. The session will conclude with an overview of elevated treatment goals in SLE and the opportunity for additional questions to ultimately transform lupus care for your patients.This symposium is organised and funded by AstraZeneca.AZ products will be discussed. Prescribing information will be available at the meeting.

Scientific sessions at CORA 2023 provide an excellent platform for renowned experts in their fields to discuss important issues. Each lecturer will give a 15-17-minute long presentation followed by a short Q&A with the audience led by the chairperson.

Scientific sessions at CORA 2023 provide an excellent platform for renowned experts in their fields to discuss important issues. Each lecturer will give a 12-minute long presentation followed by a short Q&A with the audience led by the chairperson.